Effects of imiquimod on macrophages by transcriptomic analysis
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1306094 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Imiquimod is a small-molecule immunomodulator with anti-tumor effects, and its anti-tumor activity mainly relies on its immunomodulatory capacity, including activating dendritic cells， T cells, natural killer cells, and promoting the migration of antigen-presenting cells. In this study, we pretreated mouse bone marrow-derived macrophages (BMDMs) with imiquimod for 24 hours and conducted transcriptomic analysis to explore the mechanism by which imiquimod regulates macrophages to exert anti-tumor effects. We found that imiquimod pretreatment of macrophages upregulated multiple signaling pathways, with the most significant being immune regulation-related signaling pathways. Notably, pathways such as the NF-κB pathway, Toll-like receptor (TLR) pathway were significantly upregulated. We infer that imiquimod activates TLR pathway and the downstream NF-κB pathway, promoting the polarization of macrophages to a pro-inflammatory phenotype and exerting anti-tumor effects.
2025-08-14 | GSE305492 | GEO
Project description:We carry out a comparative proteomic analysis of human bronchial epithelial cells from patients clinically treated or not with inhaled budesonide and stimulated or not with the viral mimic Poly(I:C).We also wanted to investigate the potential anti-viral effects of imiquimod, a TLR7 agonist, on the bronchial epithelial cells proteome in vitro.
2021-11-22 | PXD029135 | Pride
Project description:Analysis of effects of polyrotaxane on macrophages
| PRJNA609748 | ENA
Project description:Transcriptomic analysis of human macrophages in 3D
| PRJNA513306 | ENA
Project description:We provide a new psoriasis mouse model which is induced by p38 activation in skin. We compared the individual transcriptomic profiles of anisomycin and imiquimod-induced dermatitis. We used microarrays to compare the gene expression pattern between anisomycin- and imiquimod- induced dermatitis.
2019-02-15 | GSE110658 | GEO
Project description:Imiquimod is a Toll-like receptor (TLR)-7 agonist capable of inducing complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We hypothesized that the characterization of the early transcriptional events induced by imiquimod may provide insights about immunological events preceding acute tissue and/or tumor rejection. We report a paired analysis of adjacent punch biopsies obtained pre- and post-treatment from 36 patients with BCC subjected to local application of imiquimod (N = 22) or vehicle cream (N=14) in a blinded, randomized protocol. Four treatments were assessed (q12 applications for 2 or 4 days, or q24 hrs for 4 or 8 days). RNA was amplified and hybridized to 17.5K cDNA arrays. All treatment schedules similarly affected the transcriptional profile of BCC; however, the q12 X 4days regimen, associated with highest effectiveness, induced the most changes with 637 genes unequivocally stimulated by imiquimod. A minority of transcripts (98 genes) confirmed previous reports of interferon-Â involvement. The remaining 539 genes portrayed additional immunological functions predominantly involving the activation of cellular innate and adaptive immune-effector mechanisms. Importantly, these effector signatures recapitulate previous observations of tissue rejection in the context of cancer immunotherapy, acute allograft rejection and autoimmunity. This study based on a powerful and reproducible model of cancer eradication by innate immune mechanisms provides the first insight in humans of the early transcriptional events associated with immune rejection. This model is likely representative of constant immunological pathways through which innate and adaptive immune responses combine to induce tissue destruction. Keywords: compound treatment design We report a paired analysis of adjacent punch biopsies obtained pre- and post-treatment from 36 patients with BCC subjected to local application of imiquimod (N = 22) or vehicle cream (N=14) in a blinded, randomized protocol. Four treatments were assessed (q12 applications for 2 or 4 days, or q24 hrs for 4 or 8 days). RNA was amplified and hybridized to 17.5K cDNA arrays.
2006-10-04 | E-GEOD-5121 | biostudies-arrayexpress
Project description:The goal of the study is to examine changes in tumor gene expression after imiquimod treatment. RNA was extracted from spontaneous tumors in control mice (n=4) and in imiquimod-treated mice (n=4). Gene expression was compared between the control group and the treated group. In the imiquimod treatment group, the mice received topical treatment of 5% imiquimod cream (Aldara) on shaved skin at the site of spontaneous tumors for one treatment cycle (3 consecutive days). RNA was extracted from 4 spontaneous tumors from neu-tg mice treated with topical imiquimod for 1 cycle and 4 spontaneous tumors from control mice
2010-06-24 | E-GEOD-20032 | biostudies-arrayexpress
Project description:Transcriptomic analysis of airway macrophages from preschool wheeze
| PRJNA602540 | ENA
Project description:Transcriptomic analysis of WT and POLG mutator macrophages
| PRJNA721451 | ENA
Project description:Molecular analysis in imiquimod (IMQ)-induced psoriasis model
| PRJNA639875 | ENA